WBC

WBC Drug Delivery Technologies was a biotechnology company focused on the development of innovative drug delivery systems, specifically targeting the oral-transmucosal administration of large molecules. The company's core technology was designed to enable the delivery of complex biologics, such as vaccines and large proteins, which traditionally require injection. By utilizing a proprietary alginate-based film technology, WBC aimed to provide a non-invasive and more patient-friendly alternative for drug administration. In 2019, the company was acquired by Klaria Pharma to integrate its large-molecule delivery capabilities into Klaria's existing transmucosal film platform.